Transcatheter aortic valve replacement in very severe aortic stenosis: a systematic review and meta-analysis
Year: 2026
Type: article
Study designs: Systematic Review, Meta-Analysis
Abstract: Patients with very severe aortic stenosis (VSAS) are regarded to carry a poorer prognosis than patients with severe aortic stenosis (SAS). While current guidelines endorse earlier aortic valve replacement, evidence supporting the safety and efficacy of transcatheter aortic valve replacement (TAVR) in this subgroup remains limited. This systematic review and meta-analysis aimed to clarify clinical outcomes following TAVR in VSAS patients. From inception to March 2025, we systematically searched Medline, Embase, Scopus and Cochrane databases, for studies comparing TAVR outcomes in SAS and VSAS. Primary endpoints included 1-year all-cause mortality and heart failure hospitalizations. Secondary endpoints included procedural complications, and 30-day outcomes. Five observational studies including 2,430 patients (1,724 with SAS and 706 with VSAS) were analyzed. The mean age was 82.4 years, with 64.5% female. VSAS was associated with lower 1-year all-cause mortality (OR = 0.73; 95% CI: 0.57–0.94) and heart failure readmissions (OR = 0.57; 95% CI: 0.36–0.92). Stroke risk trended higher in VSAS (OR = 1.72; 95% CI: 0.87–3.40), while pacemaker implantation rates, degree of paravalvular leak, and 30-day mortality were comparable. Patients with VSAS demonstrate greater benefit in terms of 1-year all-cause mortality and heart failure readmissions after TAVR compared to those with SAS, without an associated increase in procedural complications. Prospective studies with extended follow-up are required to validate these observations.
Source: BMC Cardiovascular Disorders
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,090
OpenAlex ID: W7236309533
